Rafael Meza

ORCID: 0000-0002-1076-5037 · 4 papers in corpus
article 2023
Journal of the National Cancer Institute ·doi:10.1093/jnci/djad137

Generally, risk stratification models for cancer use effect estimates from risk/protective factor analyses that have not assessed potential interactions between these exposures. We have developed a 4-criterion framework for assessing intera…

other 2023
Gynecologic Oncology ·doi:10.1016/j.ygyno.2022.10.018

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify fac…

2023
Cancer research communications ·doi:10.1158/2767-9764.crc-22-0410

The effect of risk factors on ovarian cancer differs by histotype, and the prevalence of such risk factors varies by race/ethnicity. It is not clear how ovarian cancer incidence has changed over time by histotype and race/ethnicity. We used…

2022
Journal of Clinical Oncology ·doi:10.1200/jco.21.01460

PurposeTo investigate whether a panel of circulating protein biomarkers would improve risk assessment for lung cancer screening in combination with a risk model on the basis of participant characteristics.MethodsA blinded validation study w…